Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.62 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | CA9 | Q16790 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067321 | 0.93 | CA12 (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5190585 | 0.93 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL27610884 | 0.92 | CA12 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6935247 | 0.92 | CA12 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30206955 | 0.89 | TDP1 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1063112 | 0.89 | CA12 (0.62) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL4112468 | 0.87 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6937743 | 0.87 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1063374 | 0.87 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL23735563 | 0.86 | CA12 (0.62) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| EP-1339686-A2 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | CA12 1821/4885CA1 1133/4885CA2 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.